A Phase 4 interventional study of Deucravacitinib and Placebo in Psoriasis, sponsored by Bristol-Myers Squibb. Completed at 38 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.
Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 10th largest by enrollment, is one of 4 that started in 2023, is one of 8 in phase 4, and was the 15th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Belgium and 13 more countries
Ages 12–17
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 22 more countries
Ages 40+
University of California, San Francisco · Sites in United States
Ages 18–75
Bristol-Myers Squibb · Sites in Argentina, Australia, Brazil and 10 more countries
Ages 4–18
Bristol-Myers Squibb
Ages 4–75
By country, each count listing its studies:
deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 10 · Phase 4 8
First in 2016; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 102 across the 26 interventional studies. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 8 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
42 studies in Psoriasis by Bristol-Myers Squibb: 9 open now, 14 under way, 4 of them phase 3. Of 28 finished, 10 (36%) have results posted.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2023, is one of 3 in phase 4, and was the 27th registered.
Bristol-Myers Squibb’s Psoriasis studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing deucravacitinib in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 42 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Target Disease Exceptions:
Other protocol-defined inclusion/exclusion criteria apply.
Drug: Deucravacitinib
Drug: Deucravacitinib · Other: Placebo
Specified dose on specified days.
Also known as: BMS-986165, Sotyktu
Specified dose on specified days.
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16
Dermatology Life Quality Index (DLQI) is a participant-reported Quality of Life (QoL) survey which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a 4-point scale: 0=not at all 1. a little 2. a lot 3. very much The scores are added up to give a total score between 0 and 30. A lower total score means a better quality of life.
Time frame: At Week 16
Percentage of Participants Achieving a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
The Dermatology Life Quality Index (DLQI) is a simple, 10-question survey used to measure the impact of skin conditions on a patient's quality of life. It assesses how much a skin condition affects various aspects of daily life, including symptoms, feelings, daily activities, work or school, personal relationships, and treatment. The DLQI is scored by summing the responses to its 10 questions. Each question is scored on a scale from 0 to 3: 0 = Not at all 1. = A little 2. = A lot 3. = Very much The total score ranges from 0 to 30, with higher scores indicating a greater impact on the patient's quality of life.
Time frame: At Week 16
Change From Baseline in Whole-body Itch Numerical Rating Scale (NRS) Score at Week 16
The whole-body itch Numerical Rating Scale (NRS) is a survey that participants fill out themselves. It uses an 11-point scale from 0 to 10, where 0 means 'no itch' and 10 means 'worst itch imaginable.' Participants indicate the severity of their itching from psoriasis by selecting the number that best describes the worst level of itching they experienced in the past 24 hours. A lower score means better outcomes, indicating less severe itching.
Time frame: Baseline and at Week 16
Percentage of Participants With a Static Physician's Global Assessment (s-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16
The Static Physician's Global Assessment (s-PGA) is a 5-point scale to evaluate the average severity of all psoriatic lesions based on redness, scaling, and thickness. The s-PGA measures psoriasis severity at a single point in time, without considering the initial condition. The scale rates the severity as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). A lower score means better outcomes, indicating less severe psoriasis.
Time frame: At Week 16
Number of Participants With Treatment Emergent Adverse Events (AEs) From Week 0 to Week 16
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
Time frame: From Week 0 through Week 16
Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) From Week 0 to Week 16
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From Week 0 through Week 16
Number of Participants With Laboratory Abnormalities in Potential Drug-Induced Liver Injury Tests From Week 0 to Week 16
Number of participants with laboratory abnormalities in potential drug-induced liver injury tests. ALT=Alanine aminotransferase AST=Aspartate aminotransferase ULN=Upper limit of normal
Time frame: From Week 0 through Week 16
Number of Participants With Grade 3/ Grade 4 Laboratory Abnormalities From Week 0 to Week 16
Blood samples were collected to assess the abnormalities in laboratory parameters. The laboratory parameters were graded by Common Terminology Criteria for Adverse Events (CTCAE). Grade 3=Severe; Grade 4=Life-threatening.
Time frame: From Week 0 through Week 16
Number of Participants With Abnormalities in Vital Signs From Week 0 to Week 16
Number of participants with abnormalities in vital signs including heart rate, systolic blood pressure, and diastolic blood pressure.
Time frame: From Week 0 through Week 16
Number of Participants With Clinically Significant Changes in Vital Signs From Week 0 to Week 16
Vital Sign Measurements include: Body Temperature (C), Respiratory Rate (breaths/min), Seated Blood Pressure (mmHg) and Heart Rate (beats/min). Clinically significant changes in these measurements may need medical attention as they could indicate a potential health concern.
Time frame: From Week 0 through Week 16
| Milestone | Deucravacitinib | Placebo |
|---|---|---|
| Started | 120 | 60 |
| Full analysis set sub-population | 107 | 49 |
| Completed | 119 | 59 |
| Not completed | 1 | 1 |
| Withdrew: Randomization error | 1 | 1 |
| Milestone | Deucravacitinib | Placebo |
|---|---|---|
| Started | 119 | 59 |
| Completed | 104 | 49 |
| Not completed | 15 | 10 |
| Withdrew: Withdrawal by subject | 8 | 4 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Other reason | 1 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Milestone | Deucravacitinib | Placebo |
|---|---|---|
| Started | 103 | 49 |
| Completed placebo controlled period; did not enter active treatment period | 1 | 0 |
| Completed | 87 | 41 |
| Not completed | 16 | 8 |
| Withdrew: Lost to follow-up | 5 | 4 |
| Withdrew: Withdrawal by subject | 5 | 2 |
| Withdrew: Lack of efficacy | 4 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Other reasons | 1 | 0 |
Dermatology Life Quality Index (DLQI) is a participant-reported Quality of Life (QoL) survey which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a 4-point scale: 0=not at all 1. a little 2. a lot 3. very much The scores are added up to give a total score between 0 and 30. A lower total score means a better quality of life.
| Percentage of Participants | Deucravacitinib | Placebo |
|---|---|---|
| Full Analysis Set | 33.3 (25.0 to 42.5) | 6.7 (1.8 to 16.2) |
| Full Analysis Set Sub-population | 32.7 (24.0 to 42.5) | 6.1 (1.3 to 16.9) |
The Dermatology Life Quality Index (DLQI) is a simple, 10-question survey used to measure the impact of skin conditions on a patient's quality of life. It assesses how much a skin condition affects various aspects of daily life, including symptoms, feelings, daily activities, work or school, personal relationships, and treatment. The DLQI is scored by summing the responses to its 10 questions. Each question is scored on a scale from 0 to 3: 0 = Not at all 1. = A little 2. = A lot 3. = Very much The total score ranges from 0 to 30, with higher scores indicating a greater impact on the patient's quality of life.
| Percentage of Participants | Deucravacitinib | Placebo |
|---|---|---|
| Full Analysis Set | 72.5 (63.6 to 80.3) | 53.3 (40.0 to 66.3) |
| Full Analysis Set Sub-population | 72.9 (63.4 to 81.0) | 53.1 (38.3 to 67.5) |
The whole-body itch Numerical Rating Scale (NRS) is a survey that participants fill out themselves. It uses an 11-point scale from 0 to 10, where 0 means 'no itch' and 10 means 'worst itch imaginable.' Participants indicate the severity of their itching from psoriasis by selecting the number that best describes the worst level of itching they experienced in the past 24 hours. A lower score means better outcomes, indicating less severe itching.
| Score on a Scale | Deucravacitinib | Placebo |
|---|---|---|
| Full Analysis Set | -3.8 ± 2.86 | -1.8 ± 2.78 |
| Full Analysis Set Sub-population | -3.8 ± 2.73 | -1.8 ± 2.70 |
The Static Physician's Global Assessment (s-PGA) is a 5-point scale to evaluate the average severity of all psoriatic lesions based on redness, scaling, and thickness. The s-PGA measures psoriasis severity at a single point in time, without considering the initial condition. The scale rates the severity as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). A lower score means better outcomes, indicating less severe psoriasis.
| Percentage of Participants | Deucravacitinib | Placebo |
|---|---|---|
| Percentage of Participants With a Static Physician's Global Assessment (s-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16 | 35.5 (26.5 to 45.4) | 8.2 (2.3 to 19.6) |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (AEs) From Week 0 to Week 16 | 63 | 25 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) From Week 0 to Week 16 | 3 | 1 |
Number of participants with laboratory abnormalities in potential drug-induced liver injury tests. ALT=Alanine aminotransferase AST=Aspartate aminotransferase ULN=Upper limit of normal
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| ALT or AST > 3 X ULN | 1 | 0 |
| ALT or AST > 5 X ULN | 0 | 0 |
| Total Bilirubin > 2 X ULN | 0 | 0 |
| ALT or AST > 3 X ULN and Total Bilirubin > 2 X ULN on the same day | 0 | 0 |
Blood samples were collected to assess the abnormalities in laboratory parameters. The laboratory parameters were graded by Common Terminology Criteria for Adverse Events (CTCAE). Grade 3=Severe; Grade 4=Life-threatening.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Hematology: Leukocytes (Grade 3) | 1 | 0 |
| Hematology: Platelets (Grade 4) | 1 | 0 |
| Chemistry: Potassium (Grade 3) | 1 | 0 |
Number of participants with abnormalities in vital signs including heart rate, systolic blood pressure, and diastolic blood pressure.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Heart Rate (Beats/Min): Value > 100 And Change From Baseline > 30 | 0 | 1 |
| Heart Rate (Beats/Min): Value < 55 And Change From Baseline < -15 | 0 | 0 |
| Heart Rate (Beats/Min): Not Reported | 0 | 0 |
| Systolic Blood Pressure (Mmhg): Value > 140 And Change From Baseline > 20 | 5 | 4 |
| Systolic Blood Pressure (Mmhg): Value < 90 And Change From Baseline < -20 | 0 | 0 |
| Systolic Blood Pressure (Mmhg): Not Reported | 0 | 0 |
| Diastolic Blood Pressure (Mmhg): Value > 90 And Change From Baseline > 10 | 19 | 6 |
| Diastolic Blood Pressure (Mmhg): Value < 55 And Change From Baseline < -10 | 0 | 1 |
| Diastolic Blood Pressure (Mmhg): Not Reported | 0 | 0 |
Vital Sign Measurements include: Body Temperature (C), Respiratory Rate (breaths/min), Seated Blood Pressure (mmHg) and Heart Rate (beats/min). Clinically significant changes in these measurements may need medical attention as they could indicate a potential health concern.
| Participants | Deucravacitinib | Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs From Week 0 to Week 16 | 0 | 0 |
Collected over Participants were assessed for All-cause mortality, Serious adverse events and Other adverse events for up to approximately 28 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Controlled - Deucravacitinib | 1/119 (0.8%) | 3/119 (2.5%) | 32/119 (26.9%) |
| Placebo Controlled - Placebo | 0/59 (0%) | 1/59 (1.7%) | 13/59 (22%) |
| Active Treatment - Deucravacitinib - Deucravacitinib | 1/103 (1%) | 5/103 (4.9%) | 26/103 (25.2%) |
| Active Treatment - Placebo - Deucravacitinib | 0/49 (0%) | 3/49 (6.1%) | 10/49 (20.4%) |
| Event | Placebo Controlled - Deucravacitinib | Placebo Controlled - Placebo | Active Treatment - Deucravacitinib - Deucravacitinib | Active Treatment - Placebo - Deucravacitinib |
|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/119 | 0/59 | 0/103 | 1/49 |
| PneumoniaInfections and infestations | 0/119 | 0/59 | 2/103 | 1/49 |
| Postoperative wound infectionInfections and infestations | 0/119 | 0/59 | 0/103 | 1/49 |
| Angina pectorisCardiac disorders | 0/119 | 1/59 | 0/103 | 0/49 |
| Acute coronary syndromeCardiac disorders | 0/119 | 0/59 | 1/103 | 0/49 |
| Cardiac failure congestiveCardiac disorders | 0/119 | 0/59 | 1/103 | 0/49 |
| Chest painGeneral disorders | 0/119 | 0/59 | 1/103 | 0/49 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/119 | 0/59 | 1/103 | 0/49 |
| Vertigo positionalEar and labyrinth disorders | 1/119 | 0/59 | 0/103 | 0/49 |
| DeathGeneral disorders | 1/119 | 0/59 | 0/103 | 0/49 |
| Event | Placebo Controlled - Deucravacitinib | Placebo Controlled - Placebo | Active Treatment - Deucravacitinib - Deucravacitinib | Active Treatment - Placebo - Deucravacitinib |
|---|---|---|---|---|
| COVID-19Infections and infestations | 7/119 | 2/59 | 10/103 | 2/49 |
| Upper respiratory tract infectionInfections and infestations | 4/119 | 3/59 | 8/103 | 1/49 |
| AcneSkin and subcutaneous tissue disorders | 9/119 | 0/59 | 3/103 | 2/49 |
| NasopharyngitisInfections and infestations | 8/119 | 2/59 | 4/103 | 2/49 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/119 | 1/59 | 3/103 | 3/49 |
| HeadacheNervous system disorders | 2/119 | 3/59 | 2/103 | 1/49 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/119 | 3/59 | 3/103 | 0/49 |
| SinusitisInfections and infestations | 6/119 | 0/59 | 0/103 | 0/49 |
| Age, Continuous(Years) | Deucravacitinib | Placebo | Total |
|---|---|---|---|
| Mean | 49.1 ± 14.92 | 47.5 ± 13.55 | 48.6 ± 14.46 |
| Sex: Female, Male(Participants) | Deucravacitinib | Placebo | Total |
|---|---|---|---|
| Female | 48 | 20 | 68 |
| Male | 72 | 40 | 112 |
| Ethnicity (NIH/OMB)(Participants) | Deucravacitinib | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 34 | 22 | 56 |
| Not Hispanic or Latino | 86 | 36 | 122 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Deucravacitinib | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 1 | 6 |
| Black or African American | 3 | 6 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| White | 108 | 50 | 158 |
| Other | 2 | 3 | 5 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol-Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Jan 2023 to primary completion in Aug 2024, 18 months.
Results were first posted in Sep 2025, 1 year after primary completion.
Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 18 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib